ADIL has a genetically targeted alcohol-use-disorder drug candidate, a proposed European partner, and a possible simpler Phase 3 path, but the company has no product revenue and cash only into the second half of 2026.
References
Sources used in this report
SEC APISEC submissions JSON2026-05-14 · Issuer identity, ticker, exchange, CIK, SIC, filer status, and filing recency.SEC APISEC companyfacts JSON2026-05-14 · XBRL cross-check for cash, assets, liabilities, equity, losses, share count, and cash flow.SEC filingFY2025 Form 10-K2026-03-05 · Business model, AD04, ONWARD, regulatory strategy, AUD market context, IP, UVA license, risks, annual financials, and going concern.SEC filingQ1 2026 Form 10-Q2026-05-08 · Latest financials, cash runway, going concern, ATM sales, Phase 3 planning, Molteni framework, manufacturing commitment, and warrants.Company release furnished to SECQ1 2026 financial results release2026-05-11 · Latest business update, Q1 financial metrics, regulatory commentary, Molteni framework, IP, and funding caveats.Company release furnished to SECMolteni collaboration framework release2026-03-03 · Proposed European AD04 commercialization partnership and potential economics, subject to definitive agreement.Company release furnished to SECNasdaq compliance release2026-02-24 · Minimum-bid compliance regained after reverse split.Company release furnished to SECReverse split release2026-02-03 · 1-for-25 reverse split and Nasdaq compliance context.SEC governance filing2026 definitive proxy statement2026-01-06 · Warrant exercise proposal, dilution mechanics, record-date shares, and governance evidence.